NEW YORK (360Dx) – OptiScan Biomedical today announced its OptiScanner 6000 device for near-continuous glucose and lactate monitoring has received CE mark, allowing the firm to market it in the European Union.

The Hayward, California-based firm said it plans to launch the device later this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.